Vivos Therapeutics Inc (VVOS) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown significant revenue growth in the latest quarter, its financials remain weak with a negative net income and declining gross margin. Technical indicators do not signal a clear buying opportunity, and there are no recent news or trading trends to suggest a positive catalyst. Given the lack of strong positive signals, it is better to hold off on investing in VVOS at this time.

Technical Analysis

The MACD is slightly positive but contracting, indicating weak momentum. The RSI is neutral at 27.57, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 1.555, with key support at 1.427 and resistance at 1.683. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

Revenue increased by 75.73% YoY in Q3 2025, showing strong top-line growth.

Neutral/Negative Catalysts

Net income remains negative at -$5.4M despite improvement. Gross margin declined by 7.59% YoY. No recent news, trading trends, or significant activity from insiders or hedge funds.

Financial Performance

In Q3 2025, revenue increased to $6.78M (up 75.73% YoY), net income improved to -$5.4M (up 106.42% YoY), and EPS rose to -0.49 (up 22.50% YoY). However, gross margin dropped to 52.38% (down 7.59% YoY), indicating cost pressures.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

3 Analyst Rating

Wall Street analysts forecast VVOS stock price to rise

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 1.400

Low

2.5

Averages

High

Current: 1.400

Low

2.5

Averages

High

H.C. Wainwright

NULL -> Buy

initiated

AI Analysis

2025-11-17

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-11-17

initiated

NULL -> Buy

Reason

H.C. Wainwright initiated coverage of Vivos Therapeutics with a Buy rating and $7 price target. Vivos is a commercial-stage medical device company focused on the commercialization of non-surgical treatment of maxillofacial abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders, the analyst tells investors in a research note. The firm expects the company's new business model and initiatives to drive solid sales growth in the coming years.

Alliance Global Partners

Scott Henry

Buy -> Neutral

downgrade

2025-05-20

Reason

Alliance Global Partners

Scott Henry

Price Target

2025-05-20

downgrade

Buy -> Neutral

Reason

Alliance Global Partners analyst Scott Henry downgraded Vivos Therapeutics to Neutral from Buy with a price target of $2.25, down from $5.50. The firm views the company's visibility as low pending signs of execution for its new business model, which it says is unlikely before the second half of 2025. Vivos has limited financial resources to manage this uncertainty, the analyst tells investors in a research note. Alliance points out the company's Q1 results trailed forecasts as the business model shifts from dentists to sleep specialists.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VVOS

Unlock Now

VVOS Should I Buy

VVOS Should I Buy

Should You Buy Vivos Therapeutics Inc (VVOS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch